The purpose of this email is to remind VFC-enrolled providers that the monoclonal antibody product nirsevimab (trade name Beyfortus® manufactured by Sanofi) will be available for ordering on Friday, August 1, 2025.
Although ordering will open prior to the administration period, providers should not begin administering nirsevimab until October 1, 2025. The optimal timing for administration is shortly before the RSV season begins or within a baby's first week of life if born October through March. Protection is expected to last at least 5 months, about the length of an RSV season. The administration period will run through March 31, 2026.
We strongly encourage you to begin building your inventory so that you are well stocked and ready to begin administering doses when the RSV season starts in October.
Order Nirsevimab Here
Ordering Considerations:
- NCDHHS will review orders to ensure equitable distribution. Examples of data reviewed include geographic location, doses administered, and current inventory.
- VFC providers should consider the number of VFC doses used in a two-week period, along with the number of VFC doses in their current inventory, to determine the amount to request.
- Doses obtained from NCIP are for VFC-eligible patients only. Privately purchased stock must be used for fully insured patients.
For more information on nirsevimab administration, refer to the RSV Vaccine Available for Ordering Memo.
How to contact us:
For assistance, please contact the NCIP Help Desk by phone at 1.877.USE.NCIR (1-877-873-6247) or by email.
Thank you for your ongoing partnership and dedication to improving immunization outcomes in North Carolina.
In Health,
NC Department of Health and Human Services